Shares of Design Therapeutics, Inc. (DSGN) have gained 23.7% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $7 indicates a potential upside of 39.7%. The average comprises three short-term price targets ranging from a low of $4 to a high of $12, with a standard deviation of $4.36. While the lowest estimate ind ...